luismolina
- Healthy Biotechnology (NASDAQ:SANA) is up to ~6% in trading on Friday after announcing it will release data on several key studies later in the year.
- One of the most anticipated is UP421, an islet cell therapy for type 1 diabetes, an early-phase trial sponsored by researchers.
- “If proof of concept is achieved, we see potential for significant stock appreciation,” Citi analyst Samantha Semenkow, who rates the stock “buy,” wrote in a note. “Positive data would demonstrate viability in the case of type 1 diabetes while also providing an encouraging outlook for Sana's other hypoimmune assets.”
- The biotech company is also expected to release Phase 1 trial data on SC291, a CD19-targeted CAR T-cell therapy under investigation for B-cell-mediated autoimmune diseases, including lupus nephritis, extrarenal lupus, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
- Sana expects data from another Phase 1 trial of SC291 in B-cell malignancies to be available by the end of 2024. In addition, Phase 1 data from SC262, a CD22-targeted CAR T therapy, also for B-cell malignancies, are anticipated.
- Sana reported its second-quarter financial results on August 8.
